These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7788425)

  • 1. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients.
    Sahai J; Narang PK; Hawley-Foss N; Li RC; Kamal M; Cameron DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):274-9. PubMed ID: 7788425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.
    Li RC; Narang PK; Sahai J; Cameron W; Bianchine JR
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1566-70. PubMed ID: 9210686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients.
    Cato A; Qian J; Hsu A; Vomvouras S; Piergies AA; Leonard J; Granneman R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):466-72. PubMed ID: 9715843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.
    Knupp CA; Brater DC; Relue J; Barbhaiya RH
    J Clin Pharmacol; 1993 Oct; 33(10):912-7. PubMed ID: 8227460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
    Borin MT; Chambers JH; Carel BJ; Freimuth WW; Aksentijevich S; Piergies AA
    Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired absorption of rifabutin by concomitant administration of didanosine.
    Marzolini C; Chave JP; Telenti A; Brenas-Chinchon L; Biollaz J
    AIDS; 2001 Nov; 15(16):2203-4. PubMed ID: 11684946
    [No Abstract]   [Full Text] [Related]  

  • 13. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.
    Kazatchkine MD; Van PN; Costagliola D; Mohammed AS; Ledeine JM; Troccaz M; Belec L
    J Acquir Immune Defic Syndr; 2000 Aug; 24(5):418-24. PubMed ID: 11035612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
    Gibb D; Barry M; Ormesher S; Nokes L; Seefried M; Giaquinto C; Back D
    Br J Clin Pharmacol; 1995 May; 39(5):527-30. PubMed ID: 7669489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.
    Moyle GJ; Buss NE; Goggin T; Snell P; Higgs C; Hawkins DA
    Br J Clin Pharmacol; 2002 Aug; 54(2):178-82. PubMed ID: 12207638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex.
    Li RC; Nightingale S; Lewis RC; Colborn DC; Narang PK
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1397-402. PubMed ID: 8726008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
    Wang Y; Livingston E; Patil S; McKinney RE; Bardeguez AD; Gandia J; O'Sullivan MJ; Clax P; Huang S; Unadkat JD
    J Infect Dis; 1999 Nov; 180(5):1536-41. PubMed ID: 10515813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
    Bruzzese VL; Gillum JG; Israel DS; Johnson GL; Kaplowitz LG; Polk RE
    Antimicrob Agents Chemother; 1995 May; 39(5):1050-3. PubMed ID: 7625787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.